NASDAQ:FLXN Flexion Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Flexion Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.52 -0.55 (-4.97 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$10.51Now: $10.52▼$11.1150-Day Range$11.07MA: $12.06▼$13.4152-Week Range$5.01Now: $10.52▼$22.98Volume486,412 shsAverage Volume773,147 shsMarket Capitalization$518.67 millionP/E RatioN/ADividend YieldN/ABeta2.02 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingFlexion Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.15, Flexion Therapeutics has a forecasted upside of 110.6% from its current price of $10.52.Amount of Analyst CoverageFlexion Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesFlexion Therapeutics has received 545 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFlexion Therapeutics has received 355 “underperform” votes. (Add your “underperform” vote.)Community SentimentFlexion Therapeutics has received 60.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote “Outperform” if you believe FLXN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFlexion Therapeutics does not currently pay a dividend.Dividend GrowthFlexion Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Flexion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 17.03% of the stock of Flexion Therapeutics is held by insiders.Percentage Held by Institutions90.91% of the stock of Flexion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Flexion Therapeutics are expected to grow in the coming year, from ($2.72) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Flexion Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Flexion Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FLXN Previous Symbol CUSIPN/A CIK1419600 Webwww.flexiontherapeutics.com Phone781-305-7777Debt Debt-to-Equity Ratio12.77 Current Ratio6.60 Quick Ratio6.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$72.96 million Price / Sales7.11 Cash FlowN/A Price / Cash FlowN/A Book Value($0.53) per share Price / Book-19.85Profitability EPS (Most Recent Fiscal Year)($3.93) Net Income$-149,770,000.00 Net Margins-174.25% Return on Equity-592.50% Return on Assets-60.18%Miscellaneous Employees288 Outstanding Shares49,303,000Market Cap$518.67 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $10.52 -0.55 (-4.97 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive FLXN News and Ratings via Email Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter. Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions How has Flexion Therapeutics' stock been impacted by Coronavirus? Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLXN shares have decreased by 14.5% and is now trading at $10.52. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Flexion Therapeutics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Flexion Therapeutics. When is Flexion Therapeutics' next earnings date? Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Flexion Therapeutics. How were Flexion Therapeutics' earnings last quarter? Flexion Therapeutics Inc (NASDAQ:FLXN) released its quarterly earnings data on Wednesday, August, 5th. The specialty pharmaceutical company reported ($0.76) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.70) by $0.06. The specialty pharmaceutical company had revenue of $15.45 million for the quarter, compared to analyst estimates of $15.46 million. Flexion Therapeutics had a negative net margin of 174.25% and a negative return on equity of 592.50%. View Flexion Therapeutics' earnings history. What price target have analysts set for FLXN? 13 Wall Street analysts have issued 1-year price objectives for Flexion Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they expect Flexion Therapeutics' share price to reach $22.15 in the next year. This suggests a possible upside of 110.6% from the stock's current price. View analysts' price targets for Flexion Therapeutics. Who are some of Flexion Therapeutics' key competitors? Some companies that are related to Flexion Therapeutics include Karuna Therapeutics (KRTX), Opko Health (OPK), Zymeworks (ZYME), Corcept Therapeutics (CORT), Myovant Sciences (MYOV), CytoDyn (CYDY), Seres Therapeutics (MCRB), Akcea Therapeutics (AKCA), Intra-Cellular Therapies (ITCI), Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), CryoPort (CYRX), Revance Therapeutics (RVNC), Prestige Consumer Healthcare (PBH) and Eidos Therapeutics (EIDX). View all competitors. What other stocks do shareholders of Flexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), NVIDIA (NVDA), Micron Technology (MU), Gilead Sciences (GILD), Cara Therapeutics (CARA), TherapeuticsMD (TXMD), Aduro BioTech (ADRO), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP) and Viking Therapeutics (VKTX). Who are Flexion Therapeutics' key executives? Flexion Therapeutics' management team includes the following people: Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 68, Pay $1.06M)Dr. Neil Bodick, Consultant (Age 73, Pay $657.6k)Dr. Scott D. Kelley, Chief Medical Officer (Age 61, Pay $626.53k)Mr. David A. Arkowitz, Chief Financial Officer (Age 59)Scott Young, VP of Corp. Communications & Investor Relations What is Flexion Therapeutics' stock symbol? Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN." Who are Flexion Therapeutics' major shareholders? Flexion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (7.32%), Vanguard Group Inc. (4.61%), Orbimed Advisors LLC (3.42%), Goldman Sachs Group Inc. (1.47%), Bank of America Corp DE (1.31%) and Peregrine Capital Management LLC (1.48%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Michael D Clayman and Samuel D Colella. View institutional ownership trends for Flexion Therapeutics. Which institutional investors are selling Flexion Therapeutics stock? FLXN stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Cubist Systematic Strategies LLC, Peregrine Capital Management LLC, Nuveen Asset Management LLC, Mesirow Financial Investment Management Inc., and Uniplan Investment Counsel Inc.. View insider buying and selling activity for Flexion Therapeutics. Which institutional investors are buying Flexion Therapeutics stock? FLXN stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Wasatch Advisors Inc., Goldman Sachs Group Inc., Vanguard Group Inc., Balyasny Asset Management LLC, Bank of America Corp DE, Moody National Bank Trust Division, and Marshall Wace North America L.P.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Mark Stejbach, Michael D Clayman, and Samuel D Colella. View insider buying and selling activity for Flexion Therapeutics. How do I buy shares of Flexion Therapeutics? Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Flexion Therapeutics' stock price today? One share of FLXN stock can currently be purchased for approximately $10.52. How big of a company is Flexion Therapeutics? Flexion Therapeutics has a market capitalization of $518.67 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis. Flexion Therapeutics employs 288 workers across the globe. What is Flexion Therapeutics' official website? The official website for Flexion Therapeutics is www.flexiontherapeutics.com. How can I contact Flexion Therapeutics? Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
